Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL-LC: Ensitrelvir for Long COVID
NCT06161688Phase 2Active, not recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID-19 condition (PCC) comparing Ensitrelvir (S-217622) with Placebo (2 arms). Primary endpoint: Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Physical Health Summary at 10 days. Started Apr 2024; status: active, not recruiting.
02
Drugs
ensitrelvir
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06161688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161688.